EARLY STAGE PROSTATE CANCER—DO WE HAVE A PROBLEM WITH OVER-DETECTION, OVERTREATMENT OR BOTH?

References 

1. Cooperberg MR , Lubeck DP , Mehta SS , Carroll PR . Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) . J Urol . 2003;170:S21
   • Abstract
   • Full Text
   • Full-Text PDF (938 KB)
   • CrossRef
2. Draisma G , Boer R , Otto SJ , van der Cruijsen IW , Damhuis RA , Schroder FH , et al.   Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer . J Natl Cancer Inst . 2003;95:868
   • CrossRef
3. Cooperberg MR , Lubeck DP , Meng MV , Mehta SS , Carroll PR . The changing face of low-risk prostate cancer: trends in clinical presentation and primary management . J Clin Oncol . 2004;22:2141
   • MEDLINE
   • CrossRef
4. Harlan SR , Cooperberg MR , Elkin EP , Lubeck DP , Meng MV , Mehta SS , et al.   Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE . J Urol . 2003;170:1804
   • Abstract
   • Full Text
   • Full-Text PDF (73 KB)
   • CrossRef
5. Wei JT , Dunn RL , Sandler HM , McLaughlin PW , Montie JE , Litwin MS , et al.   Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer . J Clin Oncol . 2002;20:557
   • MEDLINE
   • CrossRef
6. Johansson JE , Andren O , Andersson SO , Dickman PW , Holmberg L , Magnuson A , et al.   Natural history of early, localized prostate cancer . JAMA . 2004;291:2713
   • CrossRef
7. Allaf ME , Carter HB . Update on watchful waiting for prostate cancer . Curr Opin Urol . 2004;14:171
   • MEDLINE
   • CrossRef
8. At 32, a decision: is cancer small enough to ignore? . The Wall Street Journal . Monday, December 20, 2004;